Braxia CEO Dr. Roger McIntyre said, “Today’s announcement is the first of what we intend to be a series of growth developments and acquisitions to our clinical network.”
Braxia Scientific Corp. is a medical research company with clinics providing and advancing ketamine and other innovative treatments for people living with depression and related mental health disorders. The company recently announced that it is pleased to announce the opening of its newest Braxia Health clinic in the Kitchener-Waterloo area of Ontario. The Braxia Health Clinic in Kitchen-Waterloo is the country’s sixth location. McIntyre also hinted that Further plans for the growth of Braxia Health clinics in Toronto and Ottawa are in the works to better service the growing unmet demand in different Canadian regions.
Braxia’s Vice-President of Operations, Kevin Kratiuk, added:
“While Braxia has been successfully managing patient loads and assuring timely care, infrastructure expansion was required to better serve our communities and address the unmet burden of treatment-resistant depression. With our new clinic and future expansion plans for our current clinics, we will be able to provide new and existing patients with more convenient access to treatment.”
Braxia’s network of physicians, specialists, and researchers, are led by top depression researchers Dr. Roger McIntyre and Dr. Joshua Rosenblat. Now, Braxia Health Kitchener-Waterloo will provide patients with greater access to Braxia’s network of physicians, specialists, and researchers. This team will deliver innovative, rapid-acting treatments like intravenous (IV) and oral ketamine and psilocybin for treatment-resistant depression (TRD). Other Braxia Health clinics additionally provide a world-class patient experience based on worldwide best practices recommendations published in the American Journal of Psychiatry by Dr. McIntrye and Dr. Rosenblat.
With positive preliminary results from Braxia’s ongoing Phase 2 multi-dose psilocybin trial in treatment-resistant depression and in response to demand resulting from the COVID-19 pandemic (which has resulted in an increase in annual referrals), the company will be expanding capacity at its new flagship centre in Toronto and its clinic in Ottawa.
In addition, Braxia Health clinics have begun to expand their present offerings to include IV and oral ketamine in all of its locations. Patients have also received psilocybin treatments as part of Braxia’s ongoing multi-dose clinical trial – the first-ever multi-dose psilocybin trial approved by Health Canada – and in conjunction with Health Canada’s special access program (SAP), which allows physicians to prescribe psilocybin to patients in need on a case-by-case basis.
In June 2022, Braxia received its first psilocybin SAP approval for a patient in Ontario, and it has since earned numerous more SAP approvals. Through its continuing multi-dose clinical trial and training of 20 therapists via the Braxia Institute for psilocybin-assisted therapy, Braxia has already treated several patients with psilocybin.
Featured Image: Megapixl © Sherryyates
